Chihiro Ohmori

Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort

Makito Miyake, Nobutaka Nishimura, Yuki Oda et al. · Japanese Journal of Clinical Oncology · 2023 · 37 citations

Medicine, Oncology, Pharmacology +17

Switch-maintenance avelumab immunotherapy following first-line chemotherapy for patients with advanced, unresectable or metastatic urothelial carcinoma: the first Japanese real-world evidence from a multicenter study

Makito Miyake, Takuto Shimizu, Yuki Oda et al. · Japanese Journal of Clinical Oncology · 2022 · 20 citations

Medicine, Oncology, Pharmacology +14

Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma

Makito Miyake, Takuto Shimizu, Nobutaka Nishimura et al. · Clinical Genitourinary Cancer · 2021 · 15 citations

Medicine, Oncology, Pharmacology +11